Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1239684
PUBLISHER: BCC Research | PRODUCT CODE: 1239684
Global Markets for Bioengineered Protein Drugs
PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Highlights:
The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.
The monoclonal antibodies (mAbs) segment of the global bioengineered protein drugs market is estimated to increase from $197.9 billion in 2022 to reach nearly $312.5 billion by 2027, at a CAGR of 9.6% from 2022 through 2027.
The peptide hormones segment of the global bioengineered protein drugs market is estimated to increase from $51.3 billion in 2022 to reach $69.9 billion by 2027, at a CAGR of 6.3% from 2022 through 2027.
Report Scope:
This report aims to provide a comprehensive study of the global market for bioengineered protein drugs, both in terms of quantitative and qualitative data, to help readers develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions regarding bioengineered protein drugs. Segmentation is based on the drug type, disease type, and region.
Industry growth drivers, restraints, trends, and opportunities in bioengineered protein drugs are also discussed in detail. The report also provides information on the bioengineered protein drug market competitive landscape, features detailed company profiles, and discusses the impact of COVID-19 on the market.
Report Includes:
- 28 data tables and 23 additional tables
- An up-to-date overview and analysis of the global markets for bioengineered protein drugs
- Analyses of the global market trends, with historic market revenue data (sales figures) from 2019-2021, estimates for 2022, forecasts for 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the emerging technology trends, opportunities and gaps estimating current and future demand for bioengineered protein drugs market, and major regions and countries involved in market developments
- Estimation of the actual market size and revenue forecast for global bioengineered protein drugs market in USD million terms, and corresponding market share analysis by drug type, disease type, and region
- In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall biopharmaceutical industry
- Discussion of the regulatory aspects and standards for bioengineered protein therapeutics, newly approved products, underlying clinical trials for all phases and list of vaccines, and the COVID-19 impact on the progress of this market
- Insight into the recent industry structure, competitive aspects of each product segment, increasing investment on R&D activities to develop new and improved therapies, market development strategies, and company value share analysis
- Identification of the major companies involved in the production and modification of protein drugs, and analysis of the company competitive landscape based on their recent developments, financial performance, and segmental revenues
- Descriptive company profiles of the leading global players, including AbbVie Inc., AstraZeneca plc, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS) Co., Pfizer Inc., Merck and Co., and Sanofi S.A.
Product Code: BIO009H
Table of Contents
Chapter 1 Introduction
- 1.1 Study Goals and Objectives
- 1.2 Scope of This Report
- 1.3 Methodology and Information Sources
- 1.4 What's New in This Update?
- 1.5 Geographic Breakdown
- 1.6 Analyst's Credentials
- 1.7 BCC Custom Research
- 1.8 Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- 3.1 Protein Drugs Overview
- 3.2 Bioengineered Protein Drugs
- 3.3 Manufacturing Technologies
- 3.3.1 Fractionation/Extraction from Natural Sources (Human/Animal)
- 3.3.2 Microbial Fermentation and Bioreactors
- 3.3.3 Transgenics
- 3.3.4 Mammalian Cell Culture
Chapter 4 Market Dynamics
- 4.1 Market Drivers
- 4.1.1 Growing and Aging Population
- 4.1.2 Increasing Prevalence of Chronic Diseases
- 4.1.3 Advancements in Manufacturing Technologies
- 4.1.4 New Product Launches and Label Expansions
- 4.1.5 Premium Pricing
- 4.1.6 Collaborations and Licensing Agreements
- 4.2 Market Challenges
- 4.2.1 Evolving Regulatory Scenario
- 4.2.2 Accelerating Biosimilars Market
Chapter 5 Market Breakdown by Drug Type
- 5.1 Overview
- 5.2 Monoclonal Antibodies (mAbs)
- 5.2.1 Types of mAbs
- 5.3 Peptide Hormones
- 5.3.1 Types of Peptide Hormones
- 5.4 Vaccines
- 5.4.1 Types of Vaccines
- 5.5 Fusion Proteins
- 5.5.1 Types of Fusion Proteins
- 5.6 Blood Factors
- 5.6.1 Types of Blood Factors
- 5.7 Peptide Antibiotics
- 5.7.1 Types of Peptide Antibiotics
- 5.8 Cytokines
- 5.8.1 Types of Cytokines
- 5.9 Therapeutic Enzymes
- 5.9.1 Types of Therapeutic Enzymes
- 5.10 Global Market for Bioengineered Protein Drugs, by Type
- 5.10.1 Monoclonal Antibodies (mAbs)
- 5.10.2 Peptide Hormones
- 5.10.3 Vaccines
- 5.10.4 Blood Factors and Peptide Antibiotics
- 5.10.5 Fusion Proteins
- 5.10.6 Cytokines
- 5.10.7 Therapeutic Enzymes
Chapter 6 Market Breakdown by Disease
- 6.1 Overview
- 6.2 Autoimmune Diseases and Other Immunodeficiency Disorders
- 6.3 Solid Tumors
- 6.4 Diabetes
- 6.4.1 Type 1 Diabetes
- 6.4.2 Type 2 Diabetes
- 6.4.3 Gestational Diabetes
- 6.5 Infectious Diseases
- 6.5.1 Pneumococcal
- 6.5.2 Diphtheria, Tetanus
- 6.5.3 Human Papillomavirus (HPV)
- 6.5.4 MMR
- 6.5.5 Influenza
- 6.5.6 Hepatitis A
- 6.5.7 Others
- 6.6 Blood Disorders
- 6.6.1 Bleeding Disorders
- 6.6.2 Anemia
- 6.6.3 Blood Cancer
- 6.6.4 Paroxysmal Nocturnal Hemoglobinuria
- 6.7 Growth Hormone Disorders, Enzyme Deficiency Disorders, and Infertility
- 6.8 Others
- 6.8.1 Osteoporosis
- 6.8.2 Asthma
- 6.8.3 Eye Disorders and Diseases
- 6.8.4 Transplants
- 6.8.5 Cardiovascular Diseases
- 6.8.6 Respiratory Syncytial Virus Infection
- 6.8.7 Skin Diseases
- 6.9 Global Market for Bioengineered Protein Drugs, by Disease
- 6.9.1 Autoimmune Diseases and Other Immunodeficiency Disorders
- 6.9.2 Solid Tumors
- 6.9.3 Diabetes
- 6.9.4 Infectious Diseases
- 6.9.5 Blood Disorders
- 6.9.6 Growth Hormone Disorders, Enzyme Disorders, and Infertility
- 6.9.7 Others
Chapter 7 Market Breakdown by Region
- 7.1 Global Markets for Bioengineered Protein Drugs, by Region
- 7.1.1 North America Market Revenue, by Drug Type
- 7.1.2 Europe Market Revenue, by Drug Type
- 7.1.3 Emerging Markets Revenue, by Drug Type
Chapter 8 Regulatory Aspects and New Approvals
- 8.1 New Approvals
- 8.1.1 Monoclonal Antibodies (mAbs)
- 8.1.2 Peptide Hormones
- 8.1.3 Vaccines
- 8.1.4 Blood factors
- 8.1.5 Peptide Antibiotics
- 8.1.6 Therapeutic Enzymes
- 8.1.7 Cytokines
- 8.1.8 Fusion Protein
Chapter 9 Competitive Landscape
- 9.1 Overview
- 9.2 Blockbuster Bioengineered Protein Pharmaceutical Brands
- 9.3 Monoclonal Antibodies
- 9.3.1 Market Share
- 9.3.2 Ten Top-Selling Monoclonal Antibodies
- 9.4 Peptide Hormones
- 9.4.1 Market Share
- 9.5 Vaccines (Excluding COVID-19)
- 9.5.1 Market Share
- 9.6 Blood Factors and Peptide Antibiotics
- 9.6.1 Key Players in Recombinant Blood Factors Market
- 9.6.2 Key players in Peptide Antibiotics Market
- 9.7 Fusion Proteins
- 9.7.1 Market Share
- 9.8 Cytokines
- 9.8.1Market Share
- 9.9 Therapeutic Enzymes
- 9.9.1 Market Share
Chapter 10 Emerging Trends/Upcoming Technologies in the Market
- 10.1 Bi- and Multi-Specific Antibodies
- 10.1.1 Oral GLP-1 Therapy
- 10.1.2 Accelerating Rare Disease Research Worldwide
- 10.2 Key Trends in Biopharmaceutical Industry
Chapter 11 Impact of COVID-19 Pandemic
- 11.1 Overview
- 11.2 Impact on Bioengineered Protein Drugs Market
- 11.2.1 Impact on the mAbs Market
- 11.2.2 Impact on Peptide Hormone Market
- 11.2.3 Impact on Vaccines Market
- 11.2.4 Impact on Blood Factors and Peptide Antibiotics Market
- 11.2.5 Impact on Fusion Protein Market
- 11.2.6 Impact on Cytokines Market
- 11.2.7 Impact on Therapeutic Enzyme Market
Chapter 12 Company Profiles
- ABBVIE INC.
- ADMA BIOLOGICS INC.
- AMGEN INC.
- ASTRAZENECA PLC
- BAYER PHARMACEUTICALS
- BIONTECH SE
- BRISTOL-MYERS SQUIBB
- CSL LTD.
- ELI LILLY AND CO.
- F. HOFFMANN-LA ROCHE AG
- GLAXOSMITHKLINE PLC
- GRIFOLS S.A.
- JOHNSON & JOHNSON
- MERCK & CO., INC.
- NOVARTIS AG
- NOVO NORDISK A/S
- OCTAPHARMA AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- SANOFI
- TAKEDA PHARMACEUTICAL CO., LTD.
Product Code: BIO009H
List of Tables
- Summary Table : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
- Table 1 : Characteristics of Large Molecule/Protein Drugs
- Table 2 : Bioengineered Protein Drugs vs. Chemically Synthesized Drugs
- Table 3 : Selected Protein Drugs Made, by Fractionation
- Table 4 : Selected Therapeutic Drugs Produced by Microbial Fermentation
- Table 5 : Selected Protein Drugs Produced, by Transgenic Animals, Plants, and Microorganisms
- Table 6 : Selected Protein Drugs Made, by Cell Culture
- Table 7 : Number and Distribution of Persons Aged 60+, by Region, 2019 and 2050
- Table 8 : Global Pipeline Molecules, by Type, Through 2021
- Table 9 : Advantages and Disadvantages of mAbs
- Table 10 : Vaccines by Disease Type
- Table 11 : Percentage of Major Proteins Present in Different Fractions After Cohn's Fractionation Method
- Table 12 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
- Table 13 : Global Market for mAbs, by Region, Through 2027
- Table 14 : Global Market for Peptide Hormones, by Region, Through 2027
- Table 15 : Global Market for Vaccines (Excluding COVID-19 Vaccines), by Region, Through 2027
- Table 16 : Global Market for Blood Factors and Peptide Antibiotics, by Region, Through 2027
- Table 17 : Global Market for Fusion Proteins, by Region, Through 2027
- Table 18 : Global Market for Cytokines, by Region, Through 2027
- Table 19 : Global Market for Therapeutic Enzymes, by Region, Through 2027
- Table 20 : Types of Autoimmune Diseases
- Table 21 : Types of Cancer by the Tissue of Origin
- Table 22 : Estimated Numbers for All Cancers, Excluding Non-melanoma Skin Cancer, 2020
- Table 23 : Global Diabetes Estimates and Projections, 2019-2045
- Table 24 : Global Market for Bioengineered Protein Drugs, by Disease, Through 2027
- Table 25 : Global Market for Bioengineered Protein Drugs for Autoimmune Diseases and Other Immunodeficiency Disorders, by Region, Through 2027
- Table 26 : Global Market for Bioengineered Protein Drugs for Solid Tumors, by Region, Through 2027
- Table 27 : Global Market for Bioengineered Protein Drugs for Diabetes, by Region, Through 2027
- Table 28 : Global Market for Bioengineered Protein Drugs for Infectious Diseases, by Region, Through 2027
- Table 29 : Global Market for Bioengineered Protein Drugs for Blood Disorders, by Region, Through 2027
- Table 30 : Global Market Bioengineered Protein Drugs for Growth Hormone Disorders, Enzyme Disorders, and Infertility, by Region, Through 2027
- Table 31 : Global Market for Bioengineered Protein Drugs for Other Diseases, by Region, Through 2027
- Table 32 : Global Market for Bioengineered Protein Drugs, by Region, Through 2027
- Table 33 : North American Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
- Table 34 : European Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
- Table 35 : Emerging Markets for Bioengineered Protein Drugs, by Drug Type, Through 2027
- Table 36 : Newly Approved Monoclonal Antibodies (mAbs), January 2021-December 2022
- Table 37 : Newly Approved Peptide Hormones and Drugs, January 2021-December 2022
- Table 38 : Newly Approved Vaccines, January 2021-December 2022
- Table 39 : Vaccine Candidates in Clinical Phase, January 2021-December 2022
- Table 40 : Newly Approved Blood Factors, January 2021-December 2022
- Table 41 : Newly Approved Peptide Antibiotics, January 2021-December 2022
- Table 42 : Newly Approved Therapeutic Enzymes, January 2021-December 2022
- Table 43 : Newly Approved Cytokines, January 2021-December 2022
- Table 44 : Newly Approved Fusion Protein, January 2021-December 2022
- Table 45 : The 30 Top-Selling Bioengineered Protein Drugs, 2021
- Table 46 : Selected Bi-Specific Antibodies in Phase 3 Clinical Trials, 2023
- Table 47 : WHO-Approved COVID-19 Vaccine Companies, Technology Adopted
- Table 48 : Global Market Shares of Leading Vaccine Manufacturers, Including COVID-19 and Excluding COVID-19 Vaccines, 2021
- Table 49 : Eli Lilly and Co.: Business Segments
- Table 50 : Pfizer: Biopharma Business Segment
List of Figures
- Summary Figure : Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
- Figure 1 : Approved Antibody Therapeutics in the U.S. and EU, 2010-2021
- Figure 2 : Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
- Figure 3 : Global Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021
- Figure 4 : Global Market for mAbs, by Region, 2019-2027
- Figure 5 : Global Market for Peptide Hormones, by Region, 2019-2027
- Figure 6 : Global Market for Vaccines (Excluding COVID-19 Vaccines), by Region, 2019-2027
- Figure 7 : Global Market for Blood Factors and Peptide Antibiotics, by Region, 2019-2027
- Figure 8 : Global Market for Fusion Proteins, by Region, 2019-2027
- Figure 9 : Global Market for Cytokines, by Region, 2019-2027
- Figure 10 : Global Market for Therapeutic Enzymes, by Region, 2019-2027
- Figure 11 : Estimated Global Incidence of Blood Cancer, by Type, 2020
- Figure 12 : Global Market for Bioengineered Protein Drugs, by Disease, 2019-2027
- Figure 13 : Global Market Shares of Bioengineered Protein Drugs, by Disease, 2021
- Figure 14 : Global Market for Bioengineered Protein Drugs for Autoimmune Diseases and Other Immunodeficiency Disorders, by Region, 2019-2027
- Figure 15 : Global Market for Bioengineered Protein Drugs for Solid Tumors, by Region, 2019-2027
- Figure 16 : Global Market for Bioengineered Protein Drugs for Diabetes, by Region, 2019-2027
- Figure 17 : Global Market for Bioengineered Protein Drugs for Infectious Diseases, by Region, 2019-2027
- Figure 18 : Global Market for Bioengineered Protein Drugs for Blood Disorders, by Region, 2019-2027
- Figure 19 : Global Market for Bioengineered Protein Drugs for Growth Hormone Disorders, Enzyme Disorders, and Infertility, by Region, 2019-2027
- Figure 20 : Global Market for Bioengineered Protein Drugs for Other Diseases, by Region, 2019-2027
- Figure 21 : Snapshot of Global Market for Bioengineered Protein Drugs, by Region
- Figure 22 : Global Market Shares of Bioengineered Protein Drugs, by Region, 2021
- Figure 23 : North American Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
- Figure 24 : North American Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021
- Figure 25 : European Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
- Figure 26 : European Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021
- Figure 27 : Emerging Markets for Bioengineered Protein Drugs, by Drug Type, 2019-2027
- Figure 28 : Emerging Markets Shares of Bioengineered Protein Drugs, by Drug Type, 2021
- Figure 29 : NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
- Figure 30 : Share of NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
- Figure 31 : Bioengineered Protein Drug Approvals, by Drug Type, 2021 and 2022
- Figure 32 : Distribution Share of Top 50 Best-Selling Drug Brands, by Drug Type, 2021
- Figure 33 : Top 50 Best-Selling Drug Brand Revenue Share, by Drug Type, 2021
- Figure 34 : Top 50 Best-Selling Drugs Brands, by Drug Type, 2021
- Figure 35 : Global Market Shares of Monoclonal Antibodies, by Company, 2021
- Figure 36 : Ten Top-Selling Monoclonal Antibodies, 2021
- Figure 37 : Global Market Shares of Peptide Hormones, by Company, 2021
- Figure 38 : Global Market Shares of Vaccines (Excluding COVID-19), by Company, 2021
- Figure 39 : Global Market Shares of Peptide Antibiotics, by Company, 2021
- Figure 40 : Global Market Shares of Fusion Proteins, by Company, 2021
- Figure 41 : Global Market Shares of Cytokines, by Company, 2021
- Figure 42 : Global Market Shares of Therapeutic Enzymes, by Company, 2021
- Figure 43 : AbbVie Inc.: Annual Revenue, 2019-2021
- Figure 44 : AbbVie Inc.: Revenue Share, by Business Segment, 2021
- Figure 45 : AbbVie Inc.: Revenue Share, by Region, 2021
- Figure 46 : ADMA Biologics Inc.: Annual Revenue, 2019-2021
- Figure 47 : ADMA Biologics Inc.: Revenue Share, by Business Segment, 2021
- Figure 48 : ADMA Biologics Inc.: Market Shares, by Region, 2021
- Figure 49 : Amgen Inc.: Annual Revenue, 2019-2021
- Figure 50 : Amgen Inc.: Revenue Share, by Product, 2021
- Figure 51 : Amgen Inc.: Revenue Share, by Region, 2021
- Figure 52 : AstraZeneca: Annual Revenue, 2019-2021
- Figure 53 : AstraZeneca: Revenue Share, by Segment, 2021
- Figure 54 : AstraZeneca: Revenue Share, by Region, 2021
- Figure 55 : Bayer Pharmaceuticals: Annual Revenue, 2019-2021
- Figure 56 : Bayer AG: Revenue Share, by Region, 2021
- Figure 57 : BioNTech: Annual Revenue, 2020-2021
- Figure 58 : Bristol-Myers Squibb Co.: Annual Revenue, 2019-2021
- Figure 59 : Bristol-Myers Squibb Co.: Revenue Share, by Product, 2021
- Figure 60 : Bristol-Myers Squibb Co.: Revenue Share, by Region, 2021
- Figure 61 : CSL Ltd.: Annual Revenue, 2019-2021
- Figure 62 : CSL Ltd.: Revenue Share, by Country, 2021
- Figure 63 : CSL Ltd.: Revenue Share, by Business Segment, 2021
- Figure 64 : Eli Lilly and Co.: Annual Revenue, 2019-2021
- Figure 65 : Eli Lilly and Co.: Revenue Share, by Segment, 2021
- Figure 66 : Eli Lilly and Co.: Revenue Share, by Region, 2021
- Figure 67 : Roche: Pharmaceutical Division Annual Revenue, 2019-2021
- Figure 68 : Roche: Pharmaceuticals Division Revenue Share, by Therapeutic Area, 2021
- Figure 69 : Roche: Pharmaceuticals Division Revenue Share, by Region, 2021
- Figure 70 : GlaxoSmithKline plc: Pharmaceuticals and Vaccine Segment Annual Revenue, 2019-2021
- Figure 71 : GlaxoSmithKline plc: Pharmaceutical Segment Revenue Share, by Therapeutic Area, 2021
- Figure 72 : GlaxoSmithKline plc: Vaccine Segment Revenue Share, by Category, 2021
- Figure 73 : GlaxoSmithKline plc: Revenue Share, by Region, 2021
- Figure 74 : Grifols S.A.: Annual Revenue, 2019-2021
- Figure 75 : Grifols S.A.: Revenue Share, by Segment, 2021
- Figure 76 : Grifols S.A.: Revenue Share, by Region, 2021
- Figure 77 : Johnson & Johnson: Pharmaceutical Division Annual Revenue, 2019-2021
- Figure 78 : Johnson & Johnson: Pharmaceutical Division Revenue Share, by Therapeutic Area, 2021
- Figure 79 : Johnson & Johnson: Pharmaceuticals Division Revenue Share, by Region, 2021
- Figure 80 : Merck & Co., Inc.: Pharmaceutical Segment Annual Revenue, 2019-2021
- Figure 81 : Merck & Co., Inc.: Pharmaceutical Segment Revenue Share, by Product, 2021
- Figure 82 : Merck & Co., Inc.: Pharmaceutical Segment Revenue Share, by Region, 2021
- Figure 83 : Novartis: Annual Revenue, 2019-2021
- Figure 84 : Novartis: Revenue Share, by Business Segment, 2021
- Figure 85 : Novartis: Revenue Share, by Region, 2021
- Figure 86 : Novo Nordisk: Annual Revenue, 2019-2021
- Figure 87 : Novo Nordisk: Revenue Share, by Business Segment, 2021
- Figure 88 : Novo Nordisk: Revenue Share, by Region, 2021
- Figure 89 : Octapharma: Annual Revenue, 2019-2021
- Figure 90 : Pfizer: Annual Revenue, 2019-2021
- Figure 91 : Pfizer: Biopharma Business Revenue Share, by Segment, 2021
- Figure 92 : Pfizer: Revenue Share, by Region, 2021
- Figure 93 : Regeneron Pharmaceuticals Inc.: Annual Revenue, 2019-2021
- Figure 94 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Product, 2021
- Figure 95 : Sanofi: Annual Revenue, 2019-2021
- Figure 96 : Sanofi: Revenue Share, by Business Segment, 2021
- Figure 97 : Sanofi: Revenue Share, by Region, 2021
- Figure 98 : Takeda Pharmaceutical: Annual Revenue, 2020-2022
- Figure 99 : Takeda Pharmaceutical: Revenue Share, by Business Segment, 2022
- Figure 100 : Takeda Pharmaceutical: Revenue Share, by Region, 2022
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.